Cargando…

Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study

Amino acids and acylcarnitines play an important role as substrates and intermediate products in most of pathways involved in schizophrenia development such as mitochondrial dysfunction, inflammation, lipid oxidation, DNA damage, oxidative stress, and apoptosis. It seems relevant to use an integrate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mednova, Irina A., Chernonosov, Alexander A., Kasakin, Marat F., Kornetova, Elena G., Semke, Arkadiy V., Bokhan, Nikolay A., Koval, Vladimir V., Ivanova, Svetlana A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824812/ https://www.ncbi.nlm.nih.gov/pubmed/33466490 http://dx.doi.org/10.3390/metabo11010034

Ejemplares similares

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
por: Mednova, Irina A., et al.
Publicado: (2022)

Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2022)

Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko, Anastasiia S, et al.
Publicado: (2020)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
por: Boiko, Anastasiia S., et al.
Publicado: (2019)

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2020)

Serum Growth Factors in Schizophrenia Patients
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2021)

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
por: Kornetova, Elena G., et al.
Publicado: (2021)

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
por: Boiko, Anastasiia S, et al.
Publicado: (2021)

Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2020)

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2022)

Changes in Amino Acid and Acylcarnitine Plasma Profiles for Distinguishing Patients with Multiple Sclerosis from Healthy Controls
por: Kasakin, Marat F., et al.
Publicado: (2020)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
por: Pozhidaev, Ivan V., et al.
Publicado: (2020)

Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
por: Kozyrev, Evgeny A., et al.
Publicado: (2023)

The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2023)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
por: Pozhidaev, Ivan V, et al.
Publicado: (2020)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
por: Boiko, Anastasiia S., et al.
Publicado: (2021)

Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
por: Parshukova, Daria A., et al.
Publicado: (2020)

Immunoglobulins G of Patients with Schizophrenia Protects from Superoxide: Pilot Results
por: Mednova, Irina A., et al.
Publicado: (2022)

Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
por: Ermakov, Evgeny A., et al.
Publicado: (2017)

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
por: Osmanova, Diana Z., et al.
Publicado: (2019)

The Influence of Antipsychotic Treatment on the Activity of Abzymes Targeting Myelin and Levels of Inflammation Markers in Patients with Schizophrenia
por: Kamaeva, Daria A., et al.
Publicado: (2023)

Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction
por: Smirnova, Liudmila P., et al.
Publicado: (2021)

The difference in serum proteomes in schizophrenia and bipolar disorder
por: Smirnova, Liudmila, et al.
Publicado: (2019)

DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
por: Ermakov, Evgeny A., et al.
Publicado: (2015)

Genetic polymorphisms of PIP5K2A and course of schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2020)

Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2021)

Superoxide dismutase activity of serum IgG in acute illness and remission period of schizophrenia
por: Mednova, I., et al.
Publicado: (2022)

Association of separate components of the metabolic syndrome and suicidal risk in patients with schizophrenia
por: Gerasimova, V., et al.
Publicado: (2021)

PM515. The association between serotonin receptor gene polymorphisms and hyperprolactinemia in antipsychotic drug-treated schizophrenic patients
por: Ivanova, Svetlana, et al.
Publicado: (2016)

Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
por: Fedorenko, Olga Yu, et al.
Publicado: (2015)

Effects of long-term therapy with quetiapine and olanzapine on parameters of immunity and cytokine levels in patients with schizophrenia
por: Lobacheva, O., et al.
Publicado: (2021)

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
por: Fedorenko, Olga Yu., et al.
Publicado: (2022)

Effect of Complexation with Arabinogalactan on Pharmacokinetics of “Guest” Drugs in Rats: For Example, Warfarin
por: Khvostov, Mikhail V., et al.
Publicado: (2013)

Chemokine Dysregulation and Neuroinflammation in Schizophrenia: A Systematic Review
por: Ermakov, Evgeny A., et al.
Publicado: (2023)

A preliminary investigation of amino acid and acylcarnitine levels in neonates from the Tibet autonomous
por: Zhang, Chunyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pkfbpeg7110517d1dji25sb4p9